Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Selinexor is a medicine that doctors can use to help people with a certain type of cancer called multiple myeloma. Right now, doctors usually just watch and see how the cancer is doing in people with a less severe type of multiple myeloma. But there are some tests being done to see if using selinexor can help stop the cancer from getting worse in people with a higher risk of getting the more severe type of multiple myeloma. The doctors think that using selinexor might help these patients stay healthier for longer.
Selinexor is a medicine that doctors can use to help people with a certain type of cancer called multiple myeloma. Right now, doctors usually just watch and see how the cancer is doing in people with a less severe type of multiple myeloma. But there are some tests being done to see if using selinexor can help stop the cancer from getting worse in people with a higher risk of getting the more severe type of multiple myeloma. The doctors think that using selinexor might help these patients stay healthier for longer.
*Third Opinion AI Generated Synopsis
Trial Summary
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating interventions to delay progression to multiple myeloma and prevent or delay disease related outcomes. A subset of patients with intermediate or high risk smoldering multiple myeloma have a much higher risk of progressive to multiple myeloma, while the low risk smoldering myeloma patient population has a much lower risk. This is a clinical trial investigating the use of low-dose selinexor in patients with intermediate to high-risk smoldering multiple myeloma. The investigators hypothesize that the use of selinexor in intermediate to high risk smoldering myeloma patients will help to delay progression of disease to symptomatic multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: